<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The risk of <z:mpath ids='MPATH_118'>systemic embolism</z:mpath> and <z:hpo ids='HP_0001297'>stroke</z:hpo> in patients with non-rheumatic <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (NRAF) should not be underestimated </plain></SENT>
<SENT sid="1" pm="."><plain>The annual embolic rate is approximately 5% and in those with left atrial enlargement and/or left ventricular (LV) dysfunction, or who have already had <z:mpath ids='MPATH_118'>systemic embolism</z:mpath>, this rate may be as high as 20% </plain></SENT>
<SENT sid="2" pm="."><plain>Decisions on patient management and the prophylaxis of <z:hpo ids='HP_0001297'>stroke</z:hpo> must always be individualised </plain></SENT>
<SENT sid="3" pm="."><plain>The risk of <z:mp ids='MP_0001914'>bleeding</z:mp> related to <z:chebi fb="8" ids="10033">warfarin</z:chebi> is almost certainly greater than that encountered in the previous randomised trials </plain></SENT>
<SENT sid="4" pm="."><plain>Also, clinical and echocardiographic features can further define absolute risk in an individual patient with NRAF </plain></SENT>
<SENT sid="5" pm="."><plain>Clinical markers of increased risk of embolism in patients with NRAF include older age, previous <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e>, recent <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Transthoracic echocardiography improves risk stratification and should be performed in the vast majority of patients </plain></SENT>
<SENT sid="7" pm="."><plain>Embolic risk is greatest in those with increasing <z:mp ids='MP_0004063'>left atrial dilation</z:mp>, atrial dysfunction and LV dysfunction </plain></SENT>
<SENT sid="8" pm="."><plain>Transoesophageal echocardiography sharpens the risk profile in selected patients </plain></SENT>
<SENT sid="9" pm="."><plain>Overall randomised trials show greater benefit with <z:chebi fb="8" ids="10033">warfarin</z:chebi> than aspirin </plain></SENT>
<SENT sid="10" pm="."><plain>In general, increasing age is associated with a greater incidence of structural <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e> and probably implies greater potential benefit with <z:chebi fb="8" ids="10033">warfarin</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain>Increasing age per se may not increase the risk of <z:chebi fb="8" ids="10033">warfarin</z:chebi>-related <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
<SENT sid="12" pm="."><plain>When the decision is made to warfarinise patients, at the present time data suggest that the target INR should be in the range of 2.0-3.0 </plain></SENT>
</text></document>